Application and research progress of patient-derived organoids in the multimodality treatment of pancreatic cancer
10.3760/cma.j.cn112139-20240403-00164
- VernacularTitle:肿瘤类器官在胰腺癌综合治疗中的应用及研究进展
- Author:
Hongwei WANG
1
;
Xiaoqing MA
;
Song GAO
;
Jihui HAO
Author Information
1. 天津医科大学肿瘤医院胰腺肿瘤防治中心 天津市消化系统肿瘤重点实验室 天津市恶性肿瘤临床医学研究中心 国家恶性肿瘤临床医学研究中心，天津 300060
- Keywords:
Pancreatic neoplasms;
Antineoplastic protocols;
Organoid;
High-throughput screening;
Organ-on-chip;
Tumor microenvironment
- From:
Chinese Journal of Surgery
2024;62(7):710-713
- CountryChina
- Language:Chinese
-
Abstract:
Pancreatic cancer is one of the most malignant tumors with a 5-year survival rate of 13%. Difficulty in early diagnosis,high tumor heterogeneity,high rate of drug resistance,and lack of effective new drugs are the main reasons for the poor therapeutic effect. Traditional cell line models cannot simulate the tumor environment in vitro and cannot reflect the heterogeneity of pancreatic cancer,while animal models have a long culture process and cannot be used for high-throughput screening. Pancreatic cancer organoids can be continuously expanded and cultured in vitro,which can realistically reflect the heterogeneity of pancreatic cancer and allow high-throughput drug screening,making it an ideal tool for individualized precision diagnosis and treatment of pancreatic cancer. According to recent studies on the evaluation of clinical drug efficacy using pancreatic cancer organoids,the drug sensitivity of pancreatic cancer organoids is highly consistent with the clinical efficacy,demonstrating the feasibility of drug sensitivity of pancreatic cancer organoids in guiding clinical therapy,comfirming the ability to discover potential therapeutic drugs through high-throughput drug screening of pancreatic cancer organoids. At the same time,this review reveals the importance of pancreatic cancer organoids as a model of the pancreatic cancer microenvironment for the development of new drugs and tumor microenvironment research. and the role of pancreatic cancer organoids as a model that can reflect the specific microenvironment of pancreatic cancer for new drug discovery and microenvironmental evaluation. Pancreatic cancer organoids and organ-on-chips are powerful tools for precision companion therapy and new drug discovery.
